Not logged inRETRACTION: Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture (Retraction of Vol 7, art no 9223, 2021)
Aydin, Yucel; Chedid, Milad; Chava, Srinivas; Danielle Williams, Donkita; Liu, Shuanghu; Hagedorn, Curt H.; Sumitran-Holgersson, Suchitra; Reiss, Krzysztof; Moroz, Krzysztof; Lu, Hua; Balart, Luis A.; Dash, Srikanta .png)
Share.png)
SaveElbasvir/Grazoprevir in Black Adults With Hepatitis C Virus Infection: A Pooled Analysis of Phase 2/3 Clinical TrialsZamor, Philippe J.; Vierling, John; Ghalib, Reem; Luketic, Velimir; Ravendhran, Natarajan; Balart, Luis; Robertson, Michael; Hwang, Peggy; Hanna, George J.; Nguyen, Bach-Yen; Barr, Eliav; Talwani, Rohit; Pearlman, Brian Share Save Share Save Share Save Share Save RETRACTED: Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture (Retracted Article)Aydin, Yucel; Chedid, Milad; Chava, Srinivas; Williams, Donkita Danielle; Liu, Shuanghu; Hagedorn, Curt H.; Sumitran-Holgersson, Suchitra; Reiss, Krzysztof; Moroz, Krzysztof; Lu, Hua; Balart, Luis A.; Dash, Srikanta Share Save Interferon-alpha-Induced Hepatitis C Virus Clearance Restores p53 Tumor Suppressor More Than Direct-Acting AntiviralsAydin, Yucel; Chatterjee, Animesh; Chandra, Partha K.; Chava, Srinivas; Chen, Weina; Tandon, Anamika; Dash, Asha; Chedid, Milad; Moehlen, Martin W.; Regenstein, Frederic; Balart, Luis A.; Cohen, Ari; Lu, Hua; Wu, Tong; Dash, Srikanta Share Save Share Save Share Save Share Save The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial)Poordad, Fred; Rustgi, Vinod; Brown, Robert S., Jr.; Patel, Vishal; Kugelmas, Marcelo; Regenstein, Fredric; Balart, Luis; LaBrecque, Douglas; Brown, Kimberly; Avila, Mark; Biederman, Michael; Freed, Glenn; Smith, Richard; Bernstein, Marc; Arnold, Hays; Cahan, Joel; Fink, Scott; Katkov, William; Massoumi, Hatef; Harrison, Stephen Share Save Share Save Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trialLawitz, Eric; Gane, Edward; Pearlman, Brian; Tam, Edward; Ghesquiere, Wayne; Guyader, Dominique; Alric, Laurent; Bronowicki, Jean-Pierre; Lester, Laura; Sievert, William; Ghalib, Reem; Balart, Luis; Sund, Fredrik; Lagging, Martin; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy; Howe, Anita Y. M.; Wahl, Janice; Robertson, Michael; Barr, Eliav; Haber, Barbara Share Save Persistent Hepatitis C Virus Infection Impairs Ribavirin Antiviral Activity through Clathrin-Mediated Trafficking of Equilibrative Nucleoside Transporter 1Panigrahi, Rajesh; Chandra, Partha K.; Ferraris, Pauline; Kurt, Ramazan; Song, Kyoungsub; Garry, Robert F.; Reiss, Krzysztof; Coe, Imogen R.; Furihata, Tomomi; Balart, Luis A.; Wu, Tong; Dash, Srikanta Share Save Share Save Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection-A Randomized TrialPoordad, Fred; Lawitz, Eric; Reddy, K. Rajender; Afdhal, Nezam H.; Hezode, Christophe; Zeuzem, Stefan; Lee, Samuel S.; Luis Calleja, Jose; Brown, Robert S., Jr.; Craxi, Antonio; Wedemeyer, Heiner; Nyberg, Lisa; Nelson, David R.; Rossaro, Lorenzo; Balart, Luis; Morgan, Timothy R.; Bacon, Bruce R.; Flamm, Steven L.; Kowdley, Kris V.; Deng, Weiping; Koury, Kenneth J.; Pedicone, Lisa D.; Dutko, Frank J.; Burroughs, Margaret H.; Alves, Katia; Wahl, Janice; Brass, Clifford A.; Albrecht, Janice K.; Sulkowski, Mark S.; Bailey, R.; Cooper, C.; Feinman, S. V.; Lee, S.; Marotta, P.; Tam, E.; Wong, F.; Bourliere, M.; Bronowicki, J. -P.; Hezode, C.; Tran, A.; Goeser, T.; Klass, D.; Schmid, R.; Wedemeyer, H.; Zeuzem, S.; Crax, A.; Pirisi, M.; Zuin, M.; Calleja, J. L.; Afdhal, N.; Bacon, B.; Balart, L.; Bennett, M.; Bernstein, D.; Box, T.; Boyer, T.; Brown, R.; Clain, D.; Crippin, J.; Davis, M.; Felizarta, F.; Flamm, S.; Freilich, B.; Galati, J.; Galler, G.; Ghalib, R.; Gibas, A.; Godofsky, E.; Gordon, F.; Gordon, S.; Gross, J.; Harrison, S.; Herrera, J.; Herrine, S.; Herring, R.; Jacobson, I.; Joshi, S.; Kilby, A.; King, J.; Koch, A.; Kowdley, K.; Kwo, P.; Lawitz, E.; Lebovics, E.; Lee, W.; Levin, J.; Li, X.; Luketic, V.; Mailliard, M.; McCone, J.; Mikolich, D.; Morgan, T.; Muir, A.; Mullen, K.; Nelson, D.; Nunes, F.; Nyberg, A.; Nyberg, L. M.; Pandya, P.; Pauly, M.; Peine, C.; Poleynard, G.; Poordad, F.; Poulos, J.; Pound, D.; Rabinovitz, M.; Ravendhran, N.; Reddy, R.; Reindollar, R.; Rossaro, L.; Reuben, A.; Riley, T.; Rubin, R.; Russo, M.; Ryan, M.; Saab, S.; Santoro, J.; Schmidt, W.; Sepe, T.; Sherman, K.; Sjogren, M.; Slim, J.; Smith, C.; Stein, L.; Strauss, R.; Sulkowski, M.; Vargas, H.; Vierling, J.; Witt, D.; Wu, G.; Younes, Z. Share Save Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trialsManns, Michael P.; McCone, Jonathan, Jr.; Davis, Mitchell N.; Rossaro, Lorenzo; Schiff, Eugene; Shiffman, Mitchel L.; Bacon, Bruce; Bourliere, Marc; Sulkowski, Mark S.; Bruno, Savino; Balart, Luis; Bronowicki, Jean-Pierre; Kwo, Paul; Poordad, Fred; Felizarta, Franco; Reddy, K. Rajender; Helmond, Frans A.; Sings, Heather L.; Pedicone, Lisa D.; Burroughs, Margaret; Brass, Clifford A.; Albrecht, Janice K.; Vierling, John M. Share Save Boceprevir (BOC) in Community Practice: Interim Results on Early Response and Safety from the OPTIMAL TrialPoordad, Fred; Rustgi, Vinod; Brown, Robert; Patel, Vishal; Kugelmas, Marcelo; Regenstein, Fredric; Balart, Luis; LaBrecque, Douglas; Brown, Kim; Avila, Mark; Biederman, Michael; Freed, Glenn; Smith, Richard; Bernstein, Marc; Arnold, Hays; Cahan, Joel; Fink, Scott; Katkov, William; Massoumi, Hatef; Harrison, Stephen Share Save Hepatitis C Therapy in Community Practice (OPTIMAL): An Educational Partnership Program between Academic and Community PracticesBrown, Kim; Bacon, Bruce; Balart, Luis; Bernstein, David; Brown, Robert; Flamm, Steven; Harrison, Stephen; Kugelmas, Marcelo; Kwo, Paul; LaBrecque, Douglas; Neff, Guy; Patel, Vishal; Reau, Nancy; Reddy, Rajender; Regenstein, Fredric; Schiff, Eugene; Shiffman, Mitchell; Poordad, Fred Share Save Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 InfectionMarcellin, Patrick; Cooper, Curtis; Balart, Luis; Larrey, Dominique; Box, Terry; Yoshida, Eric; Lawitz, Eric; Buggisch, Peter; Ferenci, Peter; Weltman, Martin; Labriola-Tompkins, Emily; Le Pogam, Sophie; Najera, Isabel; Thomas, Denise; Hooper, Gregory; Shulman, Nancy S.; Zhang, Ying; Navarro, Mercidita T.; Lim, Chin Yin; Brunda, Michael; Terrault, Norah A.; Yetzer, Ellen S. Share Save 
.png){kind=icon}
.png){kind=icon}
.png)
LANCET.png)
